OTREXUP Drug Patent Profile

Which patents cover Otrexup, and when can generic versions of Otrexup launch?

Otrexup is a drug marketed by Cosette and is included in one NDA. There are fifteen patents protecting this drug.

This drug has thirty-nine patent family members in fourteen countries.

The generic ingredient in OTREXUP is methotrexate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.

DrugPatentWatch^® Generic Entry Outlook for Otrexup

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2030. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OTREXUP

International Patents:	39
US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	7
Patent Applications:	5,022
Drug Prices:	Drug price information for OTREXUP
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OTREXUP
What excipients (inactive ingredients) are in OTREXUP?	OTREXUP excipients list
DailyMed Link:	OTREXUP at DailyMed

See drug prices for OTREXUP

See drug sales revenues for OTREXUP

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OTREXUP

Constraining patent/regulatory exclusivity:

11,497,753

NDA:

204824

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OTREXUP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Vanderbilt University	Phase 1
University of Virginia	Phase 1

See all OTREXUP clinical trials

Pharmacology for OTREXUP

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

US Patents and Regulatory Information for OTREXUP

OTREXUP is protected by fifteen US patents.

This potential generic entry date is based on patent 11,497,753.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-007	Mar 24, 2016		DISCN	Yes	No	9,629,959		Y
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-008	Mar 24, 2016		DISCN	Yes	No	12,357,642		Y
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-006	Mar 24, 2016		DISCN	Yes	No	8,562,564		Y

Expired US Patents for OTREXUP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-008	Mar 24, 2016	RE44846
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-001	Oct 11, 2013	RE44846
Cosette	OTREXUP	methotrexate	SOLUTION;SUBCUTANEOUS	204824-005	Nov 7, 2014	RE44846

EU/EMA Drug Approvals for OTREXUP

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Nordic Group B.V.	Nordimet	methotrexate	EMEA/H/C/003983Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.	Authorised	no	no	no	2016-08-18
Therakind (Europe) Limited	Jylamvo	methotrexate	EMEA/H/C/003756In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.	Authorised	no	no	no	2017-03-29

International Patents for OTREXUP

When does loss-of-exclusivity occur for OTREXUP?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OTREXUP around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2718053
European Patent Office	2268342
European Patent Office	2990067

OTREXUP market dynamics and financial trajectory (Q2 2026 status)

Last updated: June 24, 2026

Otrexup (methotrexate injection; single-use, prefilled autoinjector) is a specialty inflow product with a narrow US addressable market tied to methotrexate-treated rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and psoriasis. The revenue base is constrained by methotrexate’s low-cost generics across multiple dosage forms, Otrexup’s higher cost of therapy versus vial-based MTX, and payer controls on injectables. Financial trajectory is therefore dominated by (1) share shifts among MTX injectables and (2) pricing and rebate pressure rather than by new demand creation.

---

What is Otrexup (methotrexate injection) and what drives its market dynamics?

Answer: Otrexup is an MTX injection delivered via a prefilled single-use autoinjector. Demand follows the treated-patient base for RA, JIA, and psoriasis that are managed with MTX, with segment mix influenced by patient switching to injectables due to oral MTX intolerance, inadequate response, or adherence issues.

Mechanism, label scope, and how it affects commercial uptake

Otrexup’s commercial ceiling is the population eligible for MTX and willing to switch to injections. The label confines adoption to MTX therapeutic use areas rather than competing biologic pathways. That keeps Otrexup exposed to:

• MTX-first treatment standards and treat-to-target algorithms that determine how quickly patients escalate beyond MTX.
• Adherence and convenience claims tied to autoinjector use.
• Loss of exclusivity headwinds in the broader MTX landscape (even if Otrexup’s own product-specific IP remains relevant).

Key market drivers

1) Payer preference for lower unit costs. MTX is widely available as inexpensive generics in multiple presentations. Payers often manage injectable MTX through preferred drug lists, step edits, and rebate contracting. Even when Otrexup is clinically used, net pricing depends on contracting discipline.

2) Patient and clinician switching behavior. Switching to injectables is common when oral MTX causes GI intolerance or when sustained dosing is needed. Convenience can help defend share against vial MTX if payers approve Otrexup as medically necessary.

3) Safety monitoring economics. MTX therapy requires lab monitoring (CBC, LFTs, renal function), and that can shape formularies. However, that monitoring is common across MTX products and does not uniquely advantage Otrexup. It reinforces the view that differentiation is primarily delivery and access.

4) Competitive substitution inside the MTX injectable class. Otrexup competes with other MTX injectable offerings by mechanism class and therapeutic interchangeability. Market outcomes depend on pricing and access, not pharmacologic novelty.

---

How big is the competitive set for Otrexup and what shares matter most?

Answer: Otrexup’s competitive set is the broader methotrexate universe, especially injectable MTX alternatives. The main commercial battleground is not “methotrexate vs. other drugs” but “Otrexup vs vial-based and autoinjector-based MTX products” under US payer policies.

Competitive dimensions that influence share

• Unit acquisition cost vs administration logistics. Prefilled devices can lower time-to-administer but often cost more per dose. Payers focus on total cost of care and rebate structures.
• Formulary tier placement. Incentives to move members toward preferred MTX formulations limit Otrexup’s addressable contracting.
• Specialty pharmacy distribution. Injectables often travel through specialty channels; contract terms drive net-to-gross.

What is the economic “tell” in Otrexup markets

When MTX generics are present at low list prices, the product that can defend net price is the one with stronger managed-care positioning and utilization durability. For Otrexup, the revenue profile typically resembles a “defend-and-narrow” specialty asset rather than a growth engine.

---

When do Otrexup revenues peak and how does exclusivity affect financial trajectory?

Answer: Otrexup’s revenue trajectory is shaped by US patent and exclusivity timelines on the product, but the financial pattern is typically plateau-to-decline once (a) product-specific barriers erode and (b) payer substitution accelerates. The methotrexate market’s baseline commoditization means that even partial entry risk can compress net pricing quickly.

Practical exclusivity effect on revenue

• Pre-entry phase: Higher net pricing supported by managed-care contracting under brand coverage.
• Post-entry phase: Price competition triggers rebate pressure and formulary downgrade risk.
• Long tail: Residual premium can persist if the autoinjector maintains payer and patient preference, but the ceiling shrinks versus vial-based MTX.

---

What does Otrexup’s financial trajectory look like over time (brand net sales pattern)?

Answer: Otrexup’s financial trajectory is expected to follow a trend common to many specialty injectable brands with generic pressure: stable or modest growth during the protected period, followed by pressured net sales as alternatives gain access and payers lean toward lower-cost options.

Typical inflection points for Otrexup-like injectable brands

• Formulary tier changes following competitive entries.
• Contracting renegotiations that reduce net price even without immediate share loss.
• Switching due to medical policy edits (step therapy or prior authorization tightening).
• Channel adjustments like specialty pharmacy distribution concentration.

---

What is the Orange Book status of Otrexup and how does it impact generics?

Answer: Otrexup is listed in the FDA’s Orange Book with patents that delay generic and biosimilar competition to the specific approved dosage form and strength. These listings determine whether an applicant can file with patent carve-outs and whether Paragraph IV challenges can be launched.

Why Orange Book matters more for Otrexup than for many oral generics

For injectables with delivery device differentiation, generic applicants must navigate:

• Product-specific formulation and device-related barriers
• Patent coverage on the approved composition and method aspects
• FDA labeling and manufacturing equivalence requirements

What to monitor in Orange Book for financial exposure

• Remaining unexpired patents (composition, method, and use)
• Expiration clusters that can trigger “at-risk” launch planning by multiple applicants
• Whether patents are subject to terminal disclaimers or expiration “earliest by” dates

---

What patents protect Otrexup (methotrexate injection) and what is the estate strength?

Answer: Otrexup’s protected space is primarily product-specific patents in the Orange Book plus any additional device or method-of-use claims that may exist outside the Orange Book. The financial strength depends on how many independent claims survive and whether early entry is blocked on key patent numbers.

Patent estate metrics that correlate with revenue retention

• Number of independent claim families still active at any point in time
• Whether key patents are “covering” the approved drug substance, composition, and/or delivery system
• Litigation history that influences likelihood of earlier-than-expected launch

---

How does Otrexup compare with other methotrexate injectable products on economics and access?

Answer: Otrexup’s value proposition centers on device convenience and potentially improved adherence versus vial-based MTX, while its risk is payer cost containment that favors lower-cost injectables.

Comparison framework used by payers and providers

• Net price after rebates and patient assistance
• Prior authorization burden and step therapy policies
• Availability in specialty pharmacy networks
• Administration time and patient preference effects on persistence

Likely commercial outcome under competition

When payers expand preferred access to low-cost MTX injection options, Otrexup’s share can hold at the margins but typically gives up net pricing and formulary position.

---

What generic entry risks exist for Otrexup and what launch scenarios are plausible?

Answer: Generic and “authorized” substitution risks depend on Orange Book patent status and the ability of an applicant to launch without infringing remaining claims. Revenue exposure is greatest in windows where multiple barriers expire close together or where litigation settlement reduces launch friction.

Launch scenario categories for Otrexup

• Full at-expiry launch: Generic enters on the earliest permitted date.
• Design-around and carve-out launch: Launch is attempted with label or manufacturing changes aimed at avoiding certain claims.
• Settlement-driven launch date: Agreement sets a later launch date than the earliest possible.

Financial consequences by scenario

• At-expiry launches usually compress net price quickly.
• Settlement-driven launches may temporarily protect net pricing but still trigger rebate renegotiation once launch timing is visible.

---

What Otrexup patent litigation affects market access and timelines?

Answer: Otrexup’s market access timeline is affected by any Paragraph IV challenges and follow-on district court decisions that determine launch eligibility for potential generic challengers. Litigation outcomes typically drive at-risk planning by payers and specialty channels.

Litigation data points to map to revenue impact

• Filing date of Paragraph IV challenges
• Court decisions and appeal timelines
• Any final settlement agreement terms including “launch at” dates

---

How does FDA regulatory status shape Otrexup’s ability to maintain sales?

Answer: FDA status influences brand continuity and the ability to block or permit generic switching. For Otrexup, ongoing regulatory compliance and approval stability matter more than incremental label expansions because MTX demand is structurally limited by standard-of-care treatment patterns.

Regulatory factors that matter commercially

• Strength and presentation stability for substitution
• Label language that interacts with medical policy and prior authorization
• Continuity of supply (device injectors require robust manufacturing controls)

---

What is the commercial revenue exposure for Otrexup under pricing pressure?

Answer: Revenue exposure is primarily a net price and formulary position risk, since patient demand for MTX injection is transferable across products. The higher the share tied to “preferred status,” the lower the price compression risk. For Otrexup, the defensible segment is where device convenience or adherence benefits outweigh price differences under payer policy.

Revenue sensitivity drivers

• Rebate rate changes
• Contract term resets with large PBMs and integrated delivery networks
• Member migration to preferred MTX injectables
• Specialty pharmacy stocking and utilization management

---

What could change the trajectory: new entrants, payer policy, or supply?

Answer: The dominant change catalysts are competition (new injectable MTX entries or label-permitted substitution), and payer policy shifts (formulary downgrades, tighter prior authorization). Supply and device-related execution risks can also affect prescription continuity, but competition is the larger, recurring financial driver.

---

Key Takeaways

• Otrexup is a specialty injectable methotrexate brand whose market dynamics are shaped by payer preference mechanics and substitution within the MTX injectable class.
• Financial trajectory is governed less by demand growth and more by net pricing, formulary placement, and the timing of competitive entry.
• Orange Book patent status is the primary determinant of generic launch timing and hence revenue compression risk.
• Competitive pressure in methotrexate is structurally intense, so durability depends on managed-care contracting and the degree to which an autoinjector delivery option maintains preferred access.

---

FAQs

1. What payer policies most affect Otrexup utilization versus vial-based methotrexate injections?
2. How do rebate structures typically change when generic injectable methotrexate options expand?
3. What Orange Book patent expiration windows create the largest “at-risk” launch pressure for Otrexup?
4. How do specialty pharmacy distribution and prior authorization requirements influence Otrexup persistence?
5. What commercial indicators signal an approaching market share shift for Otrexup before generic entry?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-06-24).

DrugChatter Q&A for OTREXUP

Is otrexup being discontinued?
Otrexup injection manufacturing status 2025?
Otrexup injection manufacturer change 2025?
How do I use the Otrexup auto-injector for my arthritis?
How do you use the Otrexup auto-injector for RA?